2-(3-(chloromethyl)benzoyloxy)benzoic Acid Increases CD4+ Regulatory T-Cell Population and FoxP3 Expression in Lipopolysaccharide-induced Mice
Abstract
BACKGROUND: Lipopolysaccharide (LPS) has been reported to increase CD4+ regulatory T-cell (CD4+ Treg) populations. Acetylsalicylic acid (ASA) has been reported to have immunomodulatory activity, but it may induce chronic gastric ulceration. Another salicylic acid-bearing compound, 2-(3-(chloromethyl)benzoyloxy)benzoic acid (3-CH2Cl), has been reported to have less gastric mucosal damage. However, the effect of 3-CH2Cl on CD4+ Tregs in LPS-induced mice is still unknown. Therefore, the present study was conducted to investigate the immunomodulatory effect of 3-CH2Cl on CD4+ T-cell and CD4+ Treg populations as well as FoxP3 expression in LPS-induced mice.
METHODS: Synthesis of 3-CH2Cl was performed by mixing salicylic acid and chloromethylbenzoylchloride with the catalyzation of pyridine, acetone and heat. The 3-CH2Cl tablets were prepared using direct compression method. After intraperitoneal injection of 1 mg/kg BW LPS to mice, 60 mg/kg BW ASA or 60 mg/kg BW 3-CH2Cl was given orally for 3 days. The splenocyte was obtained through splenectomy and collagenase digestion. The population of CD4+ T-cells and CD4+ Tregs, as well as the splenic FoxP3 expression were determined using flow cytometry technique.
RESULTS: CD4+ T-cell populations in mice treated with LPS and 3-CH2Cl or ASA were lower than those treated with LPS merely. Meanwhile, CD4+ Treg populations and FoxP3 expression levels in mice treated with LPS and 3-CH2Cl or ASA were higher than those treated with LPS merely.
CONCLUSION: Since 3-CH2Cl could decrease CD4+ T-cell population and increase CD4+ Treg population mediated by the increase of FoxP3 expression in LPS-induced inflammation, it may act as a potential therapeutic drug to reduce inflammatory conditions.
KEYWORDS: 2-(3-(chloromethyl)benzoyloxy)benzoic acid, acetylsalicylic acid, CD4, T-regulatory cells, FoxP3, LPS
References
Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. Regulatory T cell lineage specification by the forkhead transcription factor Foxp3. Immunity. 2005; 22(3): 329-41, CrossRef.
Duggleby R, Danby RD, Madrigal JA, Saudemont A. Clinical grade regulatory CD4+ T cells (Tregs): Moving toward cellular-based immunomodulatory therapies. Front Immunol. 2018; 9: 252, CrossRef.
Brivio F, Fumagalli L, Parolini D, Messina G, Rovelli F, Rescaldani R, et al. T-helper / T-regulator lymphocyte ratio as a new immunobiological index to quantify the anticancer immune status in cancer patients. In Vivo. 2008; 22(5): 647-50, PMID.
Yao X, Ahmadzadeh M, Lu YC, Liewehr DJ, Dudley ME, Liu F, et al. Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood. 2012; 119(24): 5688-96, CrossRef.
Tanaka A, Sakaguchi S. Targeting Treg cells in cancer immunotherapy. Eur J Immunol. 2019; 49(8): 1140-46, CrossRef.
Yan JB, Luo MM, Chen ZY, He BH. The function and role of the Th17/Treg cell balance in inflammatory bowel disease. J Immunol Res. 2020; 2020: 8813558, CrossRef.
Bayati F, Mohammadi M, Valadi M, Jamshidi S, Foma AM, Sharif-Paghaleh E. The therapeutic potential of regulatory T cells: Challenges and opportunities. Front Immunol. 2021; 11: 585819, CrossRef.
Bryn T, Yaqub S, Mahic M, Henjum K, Aandahl EM, Tasken K. LPS-activated monocytes suppress T-cell immune responses and induce FOXP3+ T cells through a COX-2-PGE2-dependent mechanism. Int Immunol. 2007; 20(2): 235-45, CrossRef.
Joller N, Lozano E, Burkett P, Patel B, Xiao S, Zhu C, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity. 2014; 40(4): 569-81, CrossRef.
Okeke EB, Okwor I, Mou Z, Jia P, Uzonna JE. CD4+CD25+ regulatory T cells attenuate lipopolysaccharide-induced systemic inflammatory responses and promotes survival in murine Escherichia coli infection. Shock. 2013; 40(1): 65-73, CrossRef.
Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: Mechanisms of differentiation and function. Annu Rev Immunol. 2012; 30: 531-64, CrossRef.
Javeed A, Zhang B, Qu Y, Zhang A, Sun C, Zhang L, et al. The significantly enhanced frequency of functional CD4+CD25+Foxp3+ T regulatory cells in therapeutic dose aspirin-treated mice. Transpl Immunol. 2009; 20(4): 253-60, CrossRef.
Gregorczyk I, Maslanka T. Effect of selected non-steroidal anti-inflammatory drugs on activation-induced CD25 expression on murine CD4+ and CD8+ T cells: An in vitro study. Cen Eur J Immunol. 2019; 44(2): 109-18, CrossRef.
Mondal S, Jana M, Dasarathi S, Roy A, Pahan K. Aspirin ameliorates experimental autoimmune encephalomyelitis through interleukin-11–mediated protection of regulatory T cells. Sci Signal. 2018; 11(558): eaar8278, CrossRef.
Hussain M, Javeed A, Ashraf M, Zhao Y, Mukhtar MM and Rehman MU. Aspirin and immune system. Int Immunopharmacol. 2012; 12(1): 10-20, CrossRef.
Zhang X, Chang A, Zou Y, Xu H, Cui J, Chen Z, et al. Aspirin attenuates cardiac allograft rejection by inhibiting the maturation of dendritic cells via the NF-κB signaling pathway. Front Pharmacol. 2021; 12: 706748, CrossRef.
Ricciotti E, Fitzgerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011; 31(5): 986-1000, CrossRef.
Negara BFSP, Choi JS. Bifidobacterium lactis inhibits iNOS expression in LPS-stimulated RAW 264.7 macrophages. Indones Biomed J. 2022; 14(2): 199-205, CrossRef.
Tamayanti WD, Widharna RM, Caroline, Soekarjo B. Uji aktivitas analgesik asam 2-(3-(klorometil)benzoiloksi)benzoat dan asam 2-(4-(klorometil)benzoiloksi)benzoat pada tikus wistar jantan dengan metode plantar test. J Farm Sains Komunitas. 2016; 13(1): 15-22, CrossRef.
Caroline, Foe K, Esar SE, Soewandi A, Wihadmadyatami H, Widharna RM, et al. Evaluation of analgesic and antiplatelet activity of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid. Prostaglandins Other Lipid Mediat. 2019; 145: 106364, CrossRef.
Tjahjono Y, Karnati S, Foe K, Anggara E, Gunawan YN, Wijaya H, et al. Anti-inflammatory activity of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid in LPS-induced rat model. Prostaglandins Other Lipid Mediat. 2021; 154: 106549, CrossRef.
Hadinugroho W, Foe K, Tjahjono Y, Caroline C, Esar SY, Wijaya H, et al. Tablet formulation of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid by linear and quadratic models. ACS Omega. 2022; 38: 34045-53, CrossRef.
Tjahjono Y, Wijaya H, Esar SY, Caroline, Jafet N, Kusuma IMAB, et al. Deteksi populasi Cd3+ Cd4+ Cd25+ Foxp3+ T-regulator pada limpa mencit galur balb/c dan swiss-webster yang mudah dan cepat dengan metode flow cytometry. J Pharm Sci Pract. 2022; 9(2): 81-6, CrossRef.
Lewkowicz P, Lewkowicz N, Sasiak A, Tchórzewski H. Lipopolysaccharide-activated CD4+CD25+ T regulatory cells inhibit neutrophil function and promote their apoptosis and death. J Immunol. 2006; 177(10): 7155-63, CrossRef.
Baratelli F, Lin Y, Zhu L, Yang SC, Vourc’h NH, Zeng G, et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol. 2005; 175(3): 1483-90, CrossRef.
Hamesch K, Kamphorst EB, Strnad P, Weiskirchen R. Lipopolysaccharide-induced inflammatory liver injury in mice. Lab Anim. 2015; 49(Suppl 1): 37-46, CrossRef.
Liu Y, Fang S, Li X, Feng J, Du J, Guo L, et al. Aspirin inhibits LPS-induced macrophage activation via the NF-KB pathway. Sci Rep. 2017; 7: 11549, CrossRef.
Maturu P, Jones D, Ruteshouser EC, Hu Q, Reynolds JM, Hicks J, et al. Role of cyclooxygenase-2 pathway in creating an immunosuppresive microenvironment and in initiation and progression of Wilms’ tumor. Neoplasia. 2017; 19(3): 237-49, CrossRef.
Bergmark BA, Zelniker TA, Kim M, Mehra MR, Stewart GC, Page DS, et al. Early aspirin use, allograft rejection, and cardiac allograft vasculopathy in heart transplantation. Clin Transplant. 2021; 35(10): e14424, CrossRef.
Kartika R, Wibowo H. Impaired function of regulatory T cells in type 2 diabetes mellitus. Mol Cell Biomed Sci. 2020; 4(1): 1-9, CrossRef.
Mishra S, Srinivasan S, Ma C, Zhang N. CD8+ regulatory T cell – A mystery to be revealed. Front Immunol. 2021; 12: 708874, CrossRef.
Wang W, Hong T, Wang X, Wang R, Dju Y, Gao Q, et al. Newly found peacekeeper: Potential of CD8+ Tregs for graft-versus-host disease. Front Immunol. 2021; 12: 764786, CrossRef.
Lerret NM, Houlihan JL, Kheradmand T, Pothoven KL, Zhang ZJ, Luo X. Donor-specific CD8(+)Foxp3(+) T cells protect skin allografts and facilitate induction of conventional CD4(+)Foxp3(+) regulatory T cells. Am J Transplant. 2012; 12(9): 2335-47, CrossRef.
Sun J, Yang Y, Huo X, Zhu B, Li Z, Jiang X, et al. Efficient therapeutic function and mechanisms of human polyclonal CD8+CD103+Foxp3+ regulatory T cells on collagen-induced arthritis in mice. J Immunol Res. 2019; 2019: 8575407, CrossRef.
Beres AJ, Haribhai D, Chadwick AC, Gonyo PJ, Williams CB, Drobyski WR. CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity. J Immunol. 2012; 189(1): 464-74, CrossRef.
DOI: https://doi.org/10.18585/inabj.v15i4.2429
Copyright (c) 2023 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
